TY - JOUR
T1 - Natural history, risk factors and clinical features of primary hypogonadism in ageing men
T2 - Longitudinal Data from the European Male Ageing Study
AU - the EMAS study group
AU - Ahern, Tomás
AU - Swiecicka, Agnieszka
AU - Eendebak, Robert J.A.H.
AU - Carter, Emma L.
AU - Finn, Joseph D.
AU - Pye, Stephen R.
AU - O'Neill, Terence W.
AU - Antonio, Leen
AU - Keevil, Brian
AU - Bartfai, György
AU - Casanueva, Felipe F.
AU - Forti, Gianni
AU - Giwercman, Aleksander
AU - Han, Thang S.
AU - Kula, Krzysztof
AU - Lean, Michael E.J.
AU - Pendleton, Neil
AU - Punab, Margus
AU - Rastrelli, Giulia
AU - Rutter, Martin K.
AU - Vanderschueren, Dirk
AU - Huhtaniemi, Ilpo T.
AU - Wu, Frederick C.W.
N1 - Funding Information:
The European Male Ageing Study is funded by the Commission of the European Communities Fifth Framework Program ?Quality of Life and Management of Living Resources? Grant QLK6-CT-2001?00258 and facilitated by the Manchester Biomedical Research Centre and the NIHR Greater Manchester: Clinical Research Network. Additional support was also provided by Arthritis Research UK Centre for Epidemiology and the National Institute for Health Research and the Manchester Biomedical Research Centre. The Principal Investigator of EMAS is Professor Frederick Wu, MD; Andrology Research Unit, University of Manchester, Manchester, UK. The authors wish to thank the men who participated in the eight countries, the research/nursing staff in the eight centres: C Pott (Manchester), E Wouters (Leuven), M Nilsson (Malm?), M del Mar Fernandez (Santiago de Compostela), M Jedrzejowska, J Slowikowska-Hilczer, R Walczak-Jedrzejowska (??d?), H-M Tabo (Tartu), A Heredi (Szeged) for their data collection, and C Moseley (Manchester) for data entry and project co-ordination. Dr. D Vanderschueren is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven, Belgium.
Publisher Copyright:
© 2016 John Wiley & Sons Ltd
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Objective: In ageing men, the incidence and clinical significance of testosterone (T) decline accompanied by elevated luteinizing hormone (LH) are unclear. We describe the natural history, risk factors and clinical features associated with the development of biochemical primary hypogonadism (PHG, T < 10·5 nmol/l and LH>9·4U/l) in ageing men. Design, Patients and Measurements: A prospective observational cohort survey of 3,369 community-dwelling men aged 40-79 years, followed up for 4·3 years. Men were classified as incident (i) PHG (eugonadal [EUG, T ≥ 10·5 nmol/l] at baseline, PHG at follow-up), persistent (p) PHG (PHG at baseline and follow-up), pEUG (EUG at baseline and follow-up) and reversed (r) PHG (PHG at baseline, EUG at follow-up). Predictors and changes in clinical features associated with the development of PHG were analysed by regression models. Results: Of 1,991 men comprising the analytical sample, 97·5% had pEUG, 1·1% iPHG, 1·1% pPHG and 0·3% rPHG. The incidence of PHG was 0·2%/year. Higher age (>70 years) [OR 12·48 (1·27–122·13), P = 0·030] and chronic illnesses [OR 4·24 (1·08–16·56); P = 0·038] predicted iPHG. Upon transition from EUG to PHG, erectile function, physical vigour and haemoglobin worsened significantly. Men with pPHG had decreased morning erections, sexual thoughts and haemoglobin with increased insulin resistance. Conclusions: Primary testicular failure in men is uncommon and predicted by old age and chronic illness. Some clinical features attributable to androgen deficiency, but not others, accompanied the T decline in men who developed biochemical PHG. Whether androgen replacement can improve sexual and/or physical function in elderly men with PHG merits further study.
AB - Objective: In ageing men, the incidence and clinical significance of testosterone (T) decline accompanied by elevated luteinizing hormone (LH) are unclear. We describe the natural history, risk factors and clinical features associated with the development of biochemical primary hypogonadism (PHG, T < 10·5 nmol/l and LH>9·4U/l) in ageing men. Design, Patients and Measurements: A prospective observational cohort survey of 3,369 community-dwelling men aged 40-79 years, followed up for 4·3 years. Men were classified as incident (i) PHG (eugonadal [EUG, T ≥ 10·5 nmol/l] at baseline, PHG at follow-up), persistent (p) PHG (PHG at baseline and follow-up), pEUG (EUG at baseline and follow-up) and reversed (r) PHG (PHG at baseline, EUG at follow-up). Predictors and changes in clinical features associated with the development of PHG were analysed by regression models. Results: Of 1,991 men comprising the analytical sample, 97·5% had pEUG, 1·1% iPHG, 1·1% pPHG and 0·3% rPHG. The incidence of PHG was 0·2%/year. Higher age (>70 years) [OR 12·48 (1·27–122·13), P = 0·030] and chronic illnesses [OR 4·24 (1·08–16·56); P = 0·038] predicted iPHG. Upon transition from EUG to PHG, erectile function, physical vigour and haemoglobin worsened significantly. Men with pPHG had decreased morning erections, sexual thoughts and haemoglobin with increased insulin resistance. Conclusions: Primary testicular failure in men is uncommon and predicted by old age and chronic illness. Some clinical features attributable to androgen deficiency, but not others, accompanied the T decline in men who developed biochemical PHG. Whether androgen replacement can improve sexual and/or physical function in elderly men with PHG merits further study.
UR - http://www.scopus.com/inward/record.url?scp=84982279381&partnerID=8YFLogxK
U2 - 10.1111/cen.13152
DO - 10.1111/cen.13152
M3 - Article
C2 - 27374987
AN - SCOPUS:84982279381
SN - 0300-0664
VL - 85
SP - 891
EP - 901
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 6
ER -